Adjuvant therapy with durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) in patients with resected RCC was associated with early reductions in patient-reported quality of life (QoL), according to ...
Commercial software can’t keep pace with experimental precision when it comes to large-scale computer-algebra calculations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results